| Assessment Status |
Rapid Review Complete |
| HTA ID |
24028 |
| Drug |
Trastuzumab deruxtecan |
| Brand |
Enhertu® |
| Indication |
As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. |
| Rapid review commissioned |
17/07/2024 |
| Rapid review completed |
21/08/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care. |
